DrugPatentWatch Database Preview
LUCEMYRA Drug Patent Profile
Email this page to a colleague
When do Lucemyra patents expire, and what generic alternatives are available?
Lucemyra is a drug marketed by Uswm and is included in one NDA.
The generic ingredient in LUCEMYRA is lofexidine hydrochloride. One supplier is listed for this compound. Additional details are available on the lofexidine hydrochloride profile page.
Summary for LUCEMYRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 61 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,820 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LUCEMYRA |
| What excipients (inactive ingredients) are in LUCEMYRA? | LUCEMYRA excipients list |
| DailyMed Link: | LUCEMYRA at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LUCEMYRA
Generic Entry Date for LUCEMYRA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LUCEMYRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| RTI International | Phase 2 |
| United States Department of Defense | Phase 2 |
| Michael Debakey Veterans Affairs Medical Center | Phase 2 |
ATC Classes for LUCEMYRA
US Patents and Regulatory Information for LUCEMYRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uswm | LUCEMYRA | lofexidine hydrochloride | TABLET;ORAL | 209229-001 | May 16, 2018 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
